Cellistic

Developing safe and potent off-the-shelf NK treatments for various applications, this is what Cellistic's Echo™-NK platform offers to pharmaceutical companies. The platform streamlines the full end-to-end manufacturing process—from Master Cell Bank to drug product—utilizing standardized unit operations that include automated filling, precise labeling, and secure cryopreservation, all meticulously executed under GMP compliance. Ready to take your NK treatment development to the next level? See how: https://hubs.ly/Q03gKtpX0

A new era in cell therapy begins today. We are proud to introduce Cellistic's Echo™-NK platform—a scalable manufacturing solution for allogeneic immune cell therapies. This platform empowers therapeutic developers with a cost-effective, compliant, and feeder-free process for the scale-up and differentiation of iPSCs into NK cells, built on over 15 years of expertise in cell therapy. Echo™-NK isn’t just a step forward; it’s a bold leap toward a future where life-saving therapies become the standard option. Read the full press release here: https://hubs.ly/Q03gLgh70 #Cellistic #PressRelease #AllogeneicCellTherapy #NaturalKillerCells #NK #Manufacturing

🔍 What specific features do Allo Chassis™ off-the-shelf iPSC cell lines offer, and how do they enhance therapeutic efficacy? ⚠️ In what ways do our immune-cloaked iPSC cell lines address safety concerns related to immune rejection and patient outcomes? 💡 How does the gene editing technology used, STAR-CRISPR™, influence intellectual property (IP) considerations for the development of treatments towards commercialization?? These are the questions that Cellistic's CTO, Stefan Braam, answers in our latest blog, along with other technical insights on how our off-the-shelf iPSC cell lines derived from CD34+ and CD4+ can be further customized to fit your applications. Read the blog to get everything you need to know and access Allo Chassis™ to accelerate your allogeneic cell therapy development: https://hubs.ly/Q03dV_R90

🕚 Wednesday, the 16th of April at 1️⃣1️⃣:1️⃣5️⃣am is a moment to mark in your calendar if you're interested in deepening your understanding of how to safely scale cell therapies, making them off-the-shelf for patients with a sustainable, cost-effective development approach. Gustavo Mahler will provide key updates on Cellistic's advancements in effectively manufacturing GMP-compliant cell therapies at scale, showcasing a compelling case study at Alliance for Regenerative Medicine's #CGMED25. See you in Salone dei Cavalieri, Section 2, for Gustavo's presentation, and do not hesitate to reach out to him, Tarran Pierfelice, PhD, MBA or Peter Jaehn, Dr. if you want to discuss your application while you're in Rome! To book an appointment ▶️https://hubs.ly/Q03dCkwH0

Are you seeking a scalable, safe, and cost-effective solution to advance your cell therapy applications? All the ways lead to the Cellistic team in #Rome. Tarran Pierfelice, PhD, MBA, Gustavo Mahler and Peter Jaehn, Dr. will be in the Eternal City, participating in Alliance for Regenerative Medicine's #CGMed25. How can you integrate our Allo Chassis™ immune-cloaked iPSC cell lines into your Cell Line Development program? What are the key features of our off-the-shelf Master Cell Bank? Wondering what IP strategies come with Cellistic's STAR-CRISPR™ editing technology? Discover the answers to these questions and more about our integrated technologies for cell therapy development and manufacturing when you connect with our team in Rome. Book an appointment! 📅 https://hubs.ly/Q03dr-b10

Enable broader therapeutic applications while significantly reducing costs and timelines associated with #CellLineDevelopment: this is what Cellistic’s immune-cloaked, off-the-shelf cell lines provide to therapeutic developers. Thanks to Cade Hildreth, B.A., M.S. - BioInformant for this insightful exchange that truly higlights how Allo Chassis™ is transforming cell therapy treatments. 🔗 Want to know more? https://lnkd.in/ewUeEPCn #Cellistic #CellTherapy #OffTheShelf

Implementing GMP principles in the early stages of #CellLineDevelopment is crucial for ensuring the reliability and safety of therapeutic products through high-quality source materials. These essential principles not only enhance product consistency but also address key challenges in risk management and regulatory compliance. In their joint paper, Vincent Ernst, Quality Assurance Director, and Eric Mathieu, Senior Vice President of Operations at Cellistic, explore these advantages in detail and discuss best practices for implementation. ℹ️ https://hubs.ly/Q039cbQ70 #Cellistic #CellTherapy #iPSCs #GMPPrinciples #GMP #cGMPG

In one month, the Cellistic team will be in Rome! 🌅 As a Gold Partner of Alliance for Regenerative Medicine' #CGMed25, we’re excited to contribute to this year’s program. Our CEO, Gustavo Mahler will take the stage to share scalable models and processes that optimize time and cost efficiency in cell line development and manufacturing, supported by data-driven insights. Much like Rome wasn’t built in a day, advancing cell therapies has its challenges—but with the right strategies, the journey becomes faster and more efficient. At Cellistic, we have the blueprint to accelerate this progress without compromising on quality. Our team is looking forward to connect with industry peers and showcase the solutions driving cell therapies forward in an era of growing demand. 🗓️ https://hubs.ly/Q03bT5Fl0 See you in #Rome! Stefan Braam, Peter Jaehn, Dr., Tarran Pierfelice, PhD, MBA #Cellistic #CellTherapy #Allogeneic #iPSC

The efficiency of #AllogeneicCellTherapies heavily relies on precise gene editing, typically requiring an average of 6 to 8 different gene edits. This is where #automation plays a crucial role in #CellLineDevelopment processes, enabling the execution and validation of multiple gene modifications with high efficiency and reliability, overcoming the limitations imposed by manual genome editing. Stefan Braam, Stem Cell Expert and founder of Ncardia and Cellistic, and Suzanne Snellenberg doctor in advanced genome editing techniques and VP of Cell Line Development, review the key design criteria for a cell therapy cell line development platform and share the achievements of the CLD platform. Download the article via the link hereafter 👉 https://hubs.ly/Q03b3xDH0 #Cellistic #CellTherapy #iPSC #CLD

Today marks an exciting moment for Cellistic with Tarran Pierfelice, PhD, MBA joining us as our new Chief Commercial Officer! As the demand for transformative cell therapies grows, Tarran will be at the forefront of driving our mission to make cell therapy accessible through state-of-the-art, off-the-shelf, and scalable iPSC solutions. With over a decade of experience in biopharma and a remarkable history of building strategic partnerships, she brings a wealth of expertise to propel Cellistic’s growth and redefine what’s possible in advanced therapies. Learn more about Tarran's experience in advancing therapies on Cellistic's blog 🔗 https://hubs.ly/Q03b3k_F0 and connect with us to pave a future where cutting-edge therapies are within everyone’s reach! #Cellistic #CellTherapy #Allogeneic #iPSCs #NewAppointment #CCO